Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada

•An active surveillance found the 4CMenB vaccine to frequently cause fever and injection site reactions.•These adverse events resulted in absenteeism or medical consultations in 6.2% to 9.2% after dose 1 and 2.•Among children

Saved in:
Bibliographic Details
Published in:Vaccine 2018-12, Vol.36 (52), p.8039-8046
Main Authors: De Serres, Gaston, Billard, Marie-Noëlle, Gariépy, Marie-Claude, Rouleau, Isabelle, Toth, Eveline, Landry, Monique, Boulianne, Nicole, Gagné, Hélène, Gilca, Vladimir, Deceuninck, Geneviève, Ouakki, Manale, Skowronski, Danuta M
Format: Article
Language:English
Subjects:
4CMenB
Absenteeism
Acetaminophen
Age
Children
Clinical trials
Consultation
Fever
Health surveillance
Immunization
Incidence
Invasive meningococcal disease
Medical research
Meningococcal disease
Meningococcal vaccine
Prophylaxis
Public health
Questionnaires
Reactogenicity
Safety
Surveillance
Vaccination
Vaccine safety
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•An active surveillance found the 4CMenB vaccine to frequently cause fever and injection site reactions.•These adverse events resulted in absenteeism or medical consultations in 6.2% to 9.2% after dose 1 and 2.•Among children
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2018.10.095